Patient preference information (PPI) is a topic of interest to regulators and industry. One of
many known methods for eliciting PPI is the threshold technique (TT). However, empirical …

A favorable benefit–risk profile remains an essential requirement for marketing authorization
of medicinal drugs and devices. Furthermore, prior subjective, implicit and inconsistent ad …

Background With new technologies, health data can be collected in a variety of different
clinical, research, and public health contexts, and then can be used for a range of new …

Objective Increased treatment options and longer survival for lung cancer have generated
increased interest in patient preferences. Previous studies of patient preferences in lung …

While interest in the application of machine learning to improve healthcare has grown
tremendously in recent years, a number of barriers prevent deployment in medical practice …

Many qualitative and quantitative methods are readily available to study patient preferences
in health. These methods are now being used to inform a wide variety of decisions, and …

Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS)
should be designed and conducted to allow for inclusion of patient preferences in decision …

In health preference research (HPR) studies, data are generated by participants'/subjects'
decisions. When developing an HPR study, it is therefore important to have a clear …

Objective: Patients have unique insights and are (in-) directly affected by each decision
taken throughout the life cycle of medicinal products. Patient preference studies (PPS) …

Benefit-risk assessment is commonly conducted by drug and medical device developers
and regulators, to evaluate and communicate issues around benefit-risk balance of medical …